Description: Perspective Therapeutics, Inc., together with its subsidiaries, develops precision-targeted alpha therapies (TAT) for oncology that treats cancer patients across multiple tumor types comprising metastatic disease. The company discovers, designs, and develop its initial programs candidates consists of VMT-a-NET, that is currently in Phase 1/2a clinical trials for patients with unresectable or metastatic somatostatin receptor type 2 (SSTR2) expressing tumors that have not previously received peptide-targeted radiopharmaceutical therapy, such as Lutathera, a beta-emitting therapy; and VMT01, which is currently in Phase 1/2a clinical trials for second-line or later treatment of patients with progressive melanocortin 1 receptor (MC1R) positive metastatic melanoma. Perspective Therapeutics, Inc. has a clinical trial collaboration agreement with Bristol Myers Squibb to evaluate the safety and tolerability of [212Pb] VMT01 in combination with nivolumab in patients with histologically confirmed melanoma and positive MC1R imaging scans. The company was formerly known as Isoray, Inc. and changed its name to Perspective Therapeutics, Inc. in February 2022. Perspective Therapeutics, Inc. was founded in 1998 and is headquartered in Seattle, Washington.
Home Page: www.perspectivetherapeutics.com
2401 Elliott Avenue
Seattle,
WA
98121
United States
Phone:
206 676 0900
Officers
| Name | Title |
|---|---|
| Mr. Johan M. Spoor | CEO & Director |
| Mr. Jonathan R. Hunt | CFO and Principal Financial & Accounting Officer |
| Dr. Markus Puhlmann M.B.A., M.D. | Chief Medical Officer |
| Mr. Shane Cobb | Executive Vice President of Operations |
| Dr. Michael K. Schultz Ph.D. | Chief Science Officer |
| Ms. Annie J. Cheng | Vice President of Investor Relations |
| Mr. Andrew Bright | Executive Vice President of Brachytherapy |
| Mr. Amos Hedt BA, PGradDip | Chief Business Strategy Officer |
| Dr. Frances L. Johnson M.D. | Chief Innovation Officer |
| Mr. David Hauser Ph.D. | Senior Vice President of Clinical Operations |
Exchange: NYSE MKT
Country: US : United States of America
Currency: US Dollar ($)
| GIC Sector: | Health Care |
|---|---|
| GIC Group: | Health Care Equipment & Services |
| GIC Industry: | Health Care Equipment & Supplies |
| GIC Sub-Industry: | Health Care Equipment |
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 0.714 |
| Price-to-Sales TTM: | 150.6285 |
| IPO Date: | 2005-11-10 |
| Fiscal Year End: | December |
| Full Time Employees: | 116 |